Posaconazole (MK-5592) intravenous and oral in children (<2 years) with invasive fungal infection (MK-5592-127)

Trial Identifier: 5592-127
Sponsor: MSD
Start Date: February 2022
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Plain Language Summary

Trial Locations

Country Location
Belgium, Bruxelles-Capitale, Region de Brussels, Bruxelles-Capitale, Region de, Belgium, 1200
Belgium, Oost-Vlaanderen Gent, Oost-Vlaanderen, Belgium, 9000
Belgium, Vlaams-Brabant Leuven, Vlaams-Brabant, Belgium, 3000
Greece, Attiki Athens, Attiki, Greece, 115 27
Greece, Thessaloniki Thessaloniki, Greece, 546 42
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9112001
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Israel, N/A Tel Aviv, N/A, Israel, 6423906
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03080
Mexico, Distrito Federal Mexico City, Distrito Federal, Mexico, 04530
Mexico, Distrito Federal Mexico City, Distrito Federal, Mexico, 06720
Peru, Lima Lima, Peru, 15038
Poland, Dolnoslaskie Wrocław, Dolnoslaskie, Poland, 50-556
Poland, Warminsko-mazurskie Olsztyn, Warminsko-mazurskie, Poland, 10-561
Russian Federation, Sankt-Peterburg Saint Petersburg, Sankt-Peterburg, Russian Federation, 194291
Russian Federation, Sankt-Peterburg Saint Petersburg, Sankt-Peterburg, Russian Federation, 197022
Russian Federation, Sverdlovskaya oblast Ekaterinburg, Sverdlovskaya oblast, Russian Federation, 620149
Ukraine, Ivano-Frankivska oblast Ivano-Frankivsk, Ivano-Frankivska oblast, Ukraine, 76014
Ukraine, Kyiv Kiev, Kyiv, Ukraine, 01135
United States, CA San Diego, CA, United States, 92123
United States, FL Miami, FL, United States, 33155
United States, IL Chicago, IL, United States, 60611
United States, NC Durham, NC, United States, 27710
United States, TX Corpus Christi, TX, United States, 78411